## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($70.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. How Investors May Respond To Henry Schein (HSIC) Gaining Exclusive U.S. Rights To Drill-Free Cavity Treatment**
- Source: Simply Wall Street | 20251204T061247 | Somewhat-Bullish | Relevance: 100%
- Henry Schein has secured exclusive U.S. distribution rights for vVARDIS's drill-free Curodont Repair Fluoride Plus treatment, effective January 1, 2026. This move aligns with Henry Schein's strategy to expand into higher-margin specialties and digital solutions, augmenting its existing distribution business. While this could modestly support long-term growth, investors should consider ongoing competitive pricing pressures and the need for execution on cost savings in the near term.

**2. Hsbc Holdings PLC Raises Stake in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251204T140924 | Somewhat-Bullish | Relevance: 99%
- Hsbc Holdings PLC increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 15.9% during the second quarter, bringing its total to 155,065 shares valued at $11.33 million. The article notes that institutional investors now own 96.62% of the company, and Henry Schein recently surpassed quarterly earnings estimates with strong revenue and guidance for FY2025. Analysts currently maintain a "Hold" rating on the stock with an average price target of $76.17.

**3. 2025 Healthy Outcomes Conference: Henry Schein Canada reducing disability leave claims with wellness program**
- Source: Benefits Canada.com | 20251203T125600 | Bullish | Relevance: 99%
- Henry Schein Canada has successfully reduced disability leave claims and improved employee engagement through its comprehensive wellness program. The program, launched in 2023, focuses on five pillars: mental, physical, financial, social, and work-life balance, and has achieved a 90% employee approval rating. Investments in mental health initiatives, including wellness champions and leadership training, have also resulted in a significant return on investment for the company.

**4. Henry Schein Expands Partnership with vVARDIS**
- Source: Dentistry Today | 20251203T150646 | Bullish | Relevance: 99%
- Henry Schein, Inc. announced an expansion of its agreement with vVARDIS, granting Henry Schein exclusive U.S. distribution rights for the Curodont Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion broadens a previous agreement and will cover general dentistry, orthodontics, and pediatric dentistry nationwide. The Curodont product is a drill- and needle-free solution for early-stage cavities, addressing a significant unmet need in oral healthcare.

**5. How Investors May Respond To Henry Schein (HSIC) Gaining Exclusive U.S. Rights To Drill-Free Cavity Treatment**
- Source: Simply Wall Street | 20251204T062725 | Somewhat-Bullish | Relevance: 99%
- Henry Schein (HSIC) has secured exclusive U.S. distribution rights for vVARDIS's drill-free Curodont Repair Fluoride Plus product, expanding its role in preventive oral healthcare. This move, alongside advancements like VideaHealthâ€™s Detect AI, supports Henry Schein's strategy to shift towards higher-margin specialties and digital solutions. Despite these growth initiatives, investors should remain aware of ongoing price competition risks in core dental supplies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.0B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 13.9 |
| Current P/E | 15.0 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.9% (minimal 5-day change). Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.86% (CS: 34) | Neutral |
| RSI_14 | 59.2 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.064x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $73.62
- **Stop Loss:** $70.36 (4.4% risk)
- **Target:** $76.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $11,263.86
- **Portfolio %:** 11.26%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*